Difference between revisions of "Team:Evry"

(Trying a new homepage (inline style for the old stuff))
m (Added a link to description page)
 
(20 intermediate revisions by 2 users not shown)
Line 3: Line 3:
 
<html>
 
<html>
 
     <!-- Main Content -->
 
     <!-- Main Content -->
−
<div class='side-body hidden-xs parallax' style="width: calc(100%-250px); height: 550px; background-image: url('https://static.igem.org/mediawiki/2015/5/5d/Homepage_header_background_optimized.jpg'); background-size: cover;">
+
<div class='side-body hidden-xs parallax' style="width: calc(100%-250px); height: 550px; background: linear-gradient(rgba(0, 0, 0, 0.3), rgba(0, 0, 0, 0.3)), url('https://static.igem.org/mediawiki/2015/5/5d/Homepage_header_background_optimized.jpg'); background-size: cover;">
−
       <div style="position: relative; top: 50%;   transform: translateY(-50%);   -webkit-transform: translateY(-50%);">
+
       <div style="position: relative; top: 50%; transform: translateY(-50%); -webkit-transform: translateY(-50%);">
−
         <h1 class="text-center" style=" font-size:4em; color: #ffffff; text-shadow: 0px 0px 8px #222222;">Yeast cancer immunotherapy.</h1>
+
         <p class="text-center" style="font-weight: 400; font-size:4em; color: #ffffff; text-shadow: 0px 0px 8px #222222;">Welcome on board!</p>
−
         <p class="text-center">EVRY-GENOPOLE IGEM 2015 PROJECT</p>
+
         <p class="text-center" style="font-weight: 300; font-size:3em; color: #ffffff; text-shadow: 0px 0px 8px #222222;">iGEM Evry 2015</p>
 +
        <p class="text-center" style="font-weight: 200; font-size:2em; color: #ffffff; text-shadow: 0px 0px 8px #222222;">The YETI project to reshape the immune landscape</p>
 
       </div>
 
       </div>
 
</div>
 
</div>
 
         <div class="container">
 
         <div class="container">
 +
        <div class="side-body" id="content-body">
 
<div id='top-menu-anchor'></div>
 
<div id='top-menu-anchor'></div>
 
<div id="top-menu"></div>
 
<div id="top-menu"></div>
−
 
−
        <div class="side-body" id="content-body">
 
 
     <div class="page-header">
 
     <div class="page-header">
−
     <h1>Welcome!</h1> <!--  to our project homepage -->
+
     <h1>Let's begin with a small abstract</h1>
 
     </div>
 
     </div>
−
<h2>Abstract</h2>
+
<section class="page-section">
−
<p class="lead">Reshaping immunotherapy landscape.</p>
+
 
−
<p class="text-justify" style="font-size: 120%;">Cancer thrives by preventing the immune system from targeting tumor cells. While current immunotherapies use dendritic cells to activate T-cells towards specific tumor antigens, they remain expensive and of variable efficiency against tumor immunosuppressive environment. To address these issues, our team mainly focused on engineering a S. cerevisiae yeast immunotherapy that was ultimately tested <strong>in vivo</strong> on mice presenting melanoma.</p>
+
<p class="text-justify">
−
<p class="text-justify" style="font-size: 120%;">Three complementary strategies were combined: First, in order to modulate the tumor environment, yeast secreting immune modulators, GM-CSF and IFNgamma, were encapsulated into alginate beads and injected in tumors. Secondly, to break the immune tolerance against cancer cells, T4 and T8 lymphocytes were elicited by a yeast antigen display system. Last, to deliver cytotoxic compounds solely in the tumor environment, a yeast hypoxia bio-sensor was designed. A side project consisted in engineering E. coli to drive MAIT lymphocytes against cancer cells instead of their original targets, parasitized cells.</p>
+
Cancer thrives by preventing the <strong>immune system</strong>  from targeting tumor cells. While current immunotherapies use dendritic cells to activate T-cells towards specific tumor antigens, they remain expensive and of variable efficiency against tumor immunosuppressive environment. To develop <strong>personalized therapies</strong>, our team focused on engineering yeast <em>Saccharomyces cerevisiae</em> for targeted immunotherapy. First, we developed a <strong>software to select the best tumor antigen</strong> from patient sequencing data. Second, we created a <strong>yeast chassis</strong> to prime the immune system with the targeted antigen. This chassis was tested <em>in vitro</em> on mouse splenocytes and <em>in vivo</em> on mice presenting melanoma with significant results. Three complementary strategies were combined to induce the immune system. First, in order to modulate the <strong>tumor environment</strong>, yeast secreting the specific immune modulator IFNgamma was encapsulated into alginate beads to be injected in tumors. Secondly, to <strong>break the immune tolerance</strong> against cancer cells, T4 and T8 lymphocytes were elicited by a yeast antigen display system that can be adapted to any tumor antigen for personalized therapy. Last, to <strong>deliver cytotoxic compounds</strong> solely in the tumor environment, a yeast hypoxia bio-sensor was designed. Our <strong>standardized</strong> and <strong>customizable</strong> chassis takes advantage of these approaches to make personalized medicine a reality, with a scalable cancer therapy.</p>
−
<!--p class="lead text-justify">Our immune system can be seen as a balance between immunity and tolerance.  
+
</section>
−
This mechanism sometimes fails and lead to deleterious effects:  
+
 
−
a too important immune response can lead to food allergies or Inflammatory Bowel Disease.
+
<section class="page-section">
−
Absence of an immune response, in the other hand, plays a role in the spread of cancer cells.</p-->
+
<p class="text-justify lead">Read our <a href="https://2015.igem.org/Team:Evry/Description">project description</a> to learn more!</p>
 +
</section>
 +
 
 
<!--div id="img-div"><img src="https://static.igem.org/mediawiki/2015/8/8a/Shcema_immune_syst.jpg" class="img-rounded img-responsive"></img></div-->
 
<!--div id="img-div"><img src="https://static.igem.org/mediawiki/2015/8/8a/Shcema_immune_syst.jpg" class="img-rounded img-responsive"></img></div-->
 
<!--p class="lead">Dendritic cells can orchestrate the immune response. By acting on them using engineered micro-organisms,
 
<!--p class="lead">Dendritic cells can orchestrate the immune response. By acting on them using engineered micro-organisms,
Line 31: Line 33:
 
   <script defer="defer" type="text/javascript">
 
   <script defer="defer" type="text/javascript">
 
   // Scrolling too much = navbar appears.
 
   // Scrolling too much = navbar appears.
−
$(window).scroll(function() {
+
/*$(window).scroll(function() {
 
     if($(this).scrollTop() > 110) {
 
     if($(this).scrollTop() > 110) {
 
         $('.navbar-fixed-top').removeClass('navbar-transparent');
 
         $('.navbar-fixed-top').removeClass('navbar-transparent');
Line 37: Line 39:
 
         $('.navbar-fixed-top').addClass('navbar-transparent');
 
         $('.navbar-fixed-top').addClass('navbar-transparent');
 
     }
 
     }
−
});
+
});*/
  
 
// Parallax effect ftw
 
// Parallax effect ftw
Line 53: Line 55:
 
})();
 
})();
 
// Scroll smoothly plz.
 
// Scroll smoothly plz.
−
    $('a[href="#content-container"]').click(function(){
+
/*    $('a[href="#content-container"]').click(function(){
 
         var the_id = $(this).attr("href");
 
         var the_id = $(this).attr("href");
 
         $('html, body').animate({
 
         $('html, body').animate({
Line 59: Line 61:
 
         }, 'slow');
 
         }, 'slow');
 
         return false;
 
         return false;
−
});
+
});*/
 
   </script>
 
   </script>
 
<!-- Old content removed ! -->
 
<!-- Old content removed ! -->

Latest revision as of 20:09, 20 November 2015

   

Let's begin with a small abstract

Cancer thrives by preventing the immune system from targeting tumor cells. While current immunotherapies use dendritic cells to activate T-cells towards specific tumor antigens, they remain expensive and of variable efficiency against tumor immunosuppressive environment. To develop personalized therapies, our team focused on engineering yeast Saccharomyces cerevisiae for targeted immunotherapy. First, we developed a software to select the best tumor antigen from patient sequencing data. Second, we created a yeast chassis to prime the immune system with the targeted antigen. This chassis was tested in vitro on mouse splenocytes and in vivo on mice presenting melanoma with significant results. Three complementary strategies were combined to induce the immune system. First, in order to modulate the tumor environment, yeast secreting the specific immune modulator IFNgamma was encapsulated into alginate beads to be injected in tumors. Secondly, to break the immune tolerance against cancer cells, T4 and T8 lymphocytes were elicited by a yeast antigen display system that can be adapted to any tumor antigen for personalized therapy. Last, to deliver cytotoxic compounds solely in the tumor environment, a yeast hypoxia bio-sensor was designed. Our standardized and customizable chassis takes advantage of these approaches to make personalized medicine a reality, with a scalable cancer therapy.

Read our project description to learn more!

Scroll to top To top